RxDoctor Payments DataLook up a doctor →

Rachel Lerner, MD

Hematology & Oncology · Saint Louis Park, MNNPI 1073549986

Payments from drug & device makers

$2,267,277in general payments, 2019–2025

Across 124 payments — averaging $18,284 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.7M
  • Genentech, Inc.$218K
  • Merck$135K
  • Pharmaand GmbH$105K
  • Acerta Pharma LLC$54K
  • Mirati Therapeutics, Inc.$18K
  • plus $15K from 4 others

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis12$1,723,159
Genentech, Inc.77$218,074
Merck2$134,900
Pharmaand GmbH16$104,676
Acerta Pharma LLC5$53,615
Mirati Therapeutics, Inc.7$18,097
Bayer1$6,217
Amgen1$5,500
Pfizer2$3,026
Gilead1$12

How this compares

$2,267,277 in reported general payments places this provider in the 90th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$1,411,752
Medicare patients
374
Services billed
60,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Saint Louis Park

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →